Korean Journal of Veterinary Research (대한수의학회지)

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of clomipramine in a dog with cataplexy

  • Jeong, Soo-Yeon (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Kang, Min-Hee (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Park, Hee-Myung (Department of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
  • Received : 2012.11.17
  • Accepted : 2013.03.13
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

A 5-year-old, castrated male, Maltese was presented with history of acute flaccid paralysis. The dog was presented with sudden loss of muscle tone and involuntary movements of hind limbs. Neurologic examination revealed reduced postural reaction in the bilateral hind limbs. MRI of brain showed moderate hydrocephalus, but other examination results were normal. Based on the characteristic episodes and examination results, canine cataplexy was suspected. Treatment was initiated with clomipramine as cataplexy control. Clinical signs resolved with 3-month medication. This case demonstrates therapeutic diagnosis of cataplexy. To the author's knowledge, this is the first report of cataplexy treating with clomipramine.

Keywords

References

  1. Babcock DA, Narver EL, Dement WC, Mitler MM. Effects of imipramine, chlorimipramine, and fluoxetine on cataplexy in dogs. Pharmacol Biochem Behav 1976, 5, 599-602. https://doi.org/10.1016/0091-3057(76)90298-7
  2. Boehmer LN, Wu MF, John J, Siegel JM. Treatment with immunosuppressive and anti-inflammatory agents delays onset of canine genetic narcolepsy and reduces symptom severity. Exp Neurol 2004, 188, 292-299. https://doi.org/10.1016/j.expneurol.2004.04.006
  3. Donald CP. Plumb's veterinary drug hand book, 6th ed. pp. 287-288, Blackwell, Iowa, 2008.
  4. Etienne C. Clinical veterinary advisor: Dogs and Cats. p.744, Mosby, Missouri, 2011.
  5. Fujiki N, Yoshida Y, Ripley B, Mignot E, Nishino S. Effects of IV and ICV Hypocretin-1 (orexin A) in hypocretin recpetor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 2003, 26, 953-959. https://doi.org/10.1093/sleep/26.8.953
  6. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev 2004, 8, 355-366. https://doi.org/10.1016/j.smrv.2004.01.004
  7. Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E. Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 2001, 11, 531-539. https://doi.org/10.1101/gr.GR-1610R
  8. Lin L, Faraco J, Li R, Kadotani H, Roger W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98, 365-376. https://doi.org/10.1016/S0092-8674(00)81965-0
  9. Riehl J, Nishino S, Cederberg R, Dement WC, Mignot E. Development of cataplexy in genetically narcoleptic Dobremans. Exp Neurol 1998, 152, 292-302. https://doi.org/10.1006/exnr.1998.6847
  10. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, Barrett J, Penn R, Flanders J, deLahunta A, Lin L, Mignot E. The effect of hypocretin replacement therapy in a 3-yearold Weimaraner with narcolepsy. J Vet Intern Med 2004, 18, 586-588. https://doi.org/10.1111/j.1939-1676.2004.tb02590.x
  11. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol 1975, 32, 653-656. https://doi.org/10.1001/archneur.1975.00490520023002